EP1351573A4 - METHOD FOR MODULATING TUMOR WATCHTOWER AND METASTASIS - Google Patents

METHOD FOR MODULATING TUMOR WATCHTOWER AND METASTASIS

Info

Publication number
EP1351573A4
EP1351573A4 EP01994435A EP01994435A EP1351573A4 EP 1351573 A4 EP1351573 A4 EP 1351573A4 EP 01994435 A EP01994435 A EP 01994435A EP 01994435 A EP01994435 A EP 01994435A EP 1351573 A4 EP1351573 A4 EP 1351573A4
Authority
EP
European Patent Office
Prior art keywords
metastasis
modulation
tumor growth
methods relating
relating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01994435A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1351573A1 (en
Inventor
Francis Y Lee
Ronald Peck
David Chaplin
Ronald Pero
Klaus Edvardsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Oxi Gene Inc
Original Assignee
Bristol Myers Squibb Co
Oxi Gene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Oxi Gene Inc filed Critical Bristol Myers Squibb Co
Publication of EP1351573A1 publication Critical patent/EP1351573A1/en
Publication of EP1351573A4 publication Critical patent/EP1351573A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
EP01994435A 2000-12-22 2001-12-20 METHOD FOR MODULATING TUMOR WATCHTOWER AND METASTASIS Withdrawn EP1351573A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25819500P 2000-12-22 2000-12-22
US258195P 2000-12-22
PCT/US2001/050261 WO2002056692A1 (en) 2000-12-22 2001-12-20 Methods for modulating tumor growth and metastasis

Publications (2)

Publication Number Publication Date
EP1351573A1 EP1351573A1 (en) 2003-10-15
EP1351573A4 true EP1351573A4 (en) 2007-03-28

Family

ID=22979500

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01994435A Withdrawn EP1351573A4 (en) 2000-12-22 2001-12-20 METHOD FOR MODULATING TUMOR WATCHTOWER AND METASTASIS

Country Status (5)

Country Link
EP (1) EP1351573A4 (https=)
JP (2) JP2004523517A (https=)
AU (1) AU2002246827B2 (https=)
CA (1) CA2432792C (https=)
WO (1) WO2002056692A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2267255T3 (es) * 1998-04-03 2007-03-01 Ajinomoto Co., Inc. Agentes antitumorales.
ES2518926T3 (es) 2000-06-02 2014-11-05 Board Of Regents, The University Of Texas System Conjugados de etilendicisteína y un análogo de glucosa
HUP0302629A3 (en) 2000-10-27 2005-05-30 Aventis Pharma Sa Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
CA2432792C (en) * 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
US20060205771A1 (en) * 2002-09-25 2006-09-14 Mark Noble Caspase inhibitors as anticancer agents
WO2004032947A1 (en) * 2002-10-09 2004-04-22 Unibioscreen S.A. Extract with anti-tumor and anti-poisonous activity
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
EP2047858A1 (en) * 2007-10-10 2009-04-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Combination products for treating cancer
DK2219451T3 (en) 2007-11-21 2015-01-12 Oxigene Inc A method for the treatment of hematopoietic neoplasms
WO2009103076A1 (en) * 2008-02-15 2009-08-20 Oxigene, Inc. Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2939665B1 (fr) 2008-12-12 2011-10-07 Sanofi Aventis Combinaison antitumorale associant l'ave8062a et le docetaxel
EP3337495A4 (en) 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
CN107773556B (zh) * 2016-08-26 2020-08-18 广州安好医药科技有限公司 一种具有抗肿瘤药物功效的联合用药物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048591A1 (en) * 1999-02-16 2000-08-24 Angiogene Pharmaceuticals Ltd. Combinations for the treatment of diseases involving angiogenesis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
CA1338645C (en) 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
JP2002500227A (ja) 1998-01-09 2002-01-08 アリゾナ ボード オブ リーゼンツ コンブレタスタチンａ−４プロドラッグとそのトランス異性体
WO2000048606A1 (en) 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
CA2432792C (en) * 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048591A1 (en) * 1999-02-16 2000-08-24 Angiogene Pharmaceuticals Ltd. Combinations for the treatment of diseases involving angiogenesis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHAPLIN D J ET AL: "ANTI-VASCULAR APPROACHES TO SOLID TUMOUR THERAPY: EVALUATION OF COMBRETASTATIN A4 PHOSPHATE", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 19, no. 1A, January 1999 (1999-01-01), pages 189 - 196, XP008013078, ISSN: 0250-7005 *
HORSMAN M R ET AL: "COMBRETASTATINS NOVEL VASCULAR TARGETING DRUGS FOR IMPROVING ANTI-CANCER THERAPY COMBRETASTATINS AND CONVENTIONAL THERAPY", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, US, vol. 476, 2000, pages 311 - 323, XP008013085, ISSN: 0065-2598 *
LINGYUN LI, B.S. AND OTHERS: "Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS, vol. 42, no. 4, 1998, pages 899 - 903, XP002419739 *
NELKIN B D ET AL: "COMBRETASTATIN A-4 AND DOXORUBICIN COMBINATION TREATMENT IF EFFECTIVE IN A PRECLINICAL MODEL OF HUMAN MEDULLARY THYROID CARCINOMA", ONCOLOGY REPORTS, NATIONAL HELLENIC RESEARCH FOUNDATION, ATHENS, GR, vol. 8, no. 1, January 2001 (2001-01-01), pages 157 - 160, XP008013083, ISSN: 1021-335X *
See also references of WO02056692A1 *

Also Published As

Publication number Publication date
CA2432792C (en) 2012-04-03
AU2002246827B2 (en) 2008-02-21
WO2002056692A1 (en) 2002-07-25
CA2432792A1 (en) 2002-07-25
JP2004523517A (ja) 2004-08-05
EP1351573A1 (en) 2003-10-15
JP2009102350A (ja) 2009-05-14

Similar Documents

Publication Publication Date Title
EP1351573A4 (en) METHOD FOR MODULATING TUMOR WATCHTOWER AND METASTASIS
EP1539218A4 (en) COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
EP1552002A4 (en) APTAMER TOXIN MOLECULES AND METHOD FOR THEIR USE
EP1412417A4 (en) POLYMERNANEAN COMPOSITES AND MANUFACTURING METHOD
EP1667646A4 (en) METHOD FOR USE OF AMMONIA-OXIDATING BACTERIA
ATE359103T1 (de) Modulation des haarwuchses
DE60010824T2 (de) Katheter zur intermittierenden Selbst-Ableitung von Urin
EP1339401A4 (en) STENOPROPHILURE MATRICES AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP1408862A4 (en) ABLATION PROCESSES AND DEVICES
DE69935741D1 (de) Komplettierung von Unterdruck-Bohrlöchern
EP1562742A4 (en) Microstructures and methods of fabrication thereof
DK1252293T3 (da) Kilde til levervæv
ATE411332T1 (de) 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden
EP1737477A4 (en) PROCESS FOR USING PROBIOTIC LACTOBACILLI IN PETS
FI20012121L (fi) Akryyliaromaattien valmistus
EP1466176A4 (en) COMPOUNDS AND METHODS FOR FLUORESCENT MARKING
EP1572944A4 (en) METHOD AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF XBP-1
EP0880353A4 (en) MEANS AND METHOD FOR REGULATING THE MELANINE PRODUCTION
EP1476150A4 (en) CARBOXY FULLERES AND USE METHOD THEREFOR
AR028326A1 (es) Formacion de un gel reversible
EP1638513A4 (en) HIGHLY UNAVAILABLE CONNECTIONS AND METHOD OF USE THEREFOR
NO20023837L (no) Modulering av bendannelse
EP1401641A4 (en) BONDING MATERIALS AND MANUFACTURING METHOD AND USE THEREOF
EP1578424A4 (en) SUBSTITUTED 1-BENZOYL-3-CYANOPYRROLO1,2-A | CHINOLINES AND THEIR ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCTORS OF APOPTOSIS
EP1407049A4 (en) HISTON DEACETYLASE AND METHOD OF USE THEREOF

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030623

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101AFI20070214BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070222

17Q First examination report despatched

Effective date: 20071219

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130702